ImmunityBio (IBRX) Competitors $2.31 +0.07 (+3.13%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$2.32 +0.00 (+0.22%) As of 08/22/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IBRX vs. BBIO, VRNA, ELAN, BPMC, ROIV, GRFS, LEGN, RVMD, RYTM, and RNAShould you be buying ImmunityBio stock or one of its competitors? The main competitors of ImmunityBio include BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Elanco Animal Health (ELAN), Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Grifols (GRFS), Legend Biotech (LEGN), Revolution Medicines (RVMD), Rhythm Pharmaceuticals (RYTM), and Avidity Biosciences (RNA). These companies are all part of the "pharmaceutical products" industry. ImmunityBio vs. Its Competitors BridgeBio Pharma Verona Pharma PLC American Depositary Share Elanco Animal Health Blueprint Medicines Roivant Sciences Grifols Legend Biotech Revolution Medicines Rhythm Pharmaceuticals Avidity Biosciences BridgeBio Pharma (NASDAQ:BBIO) and ImmunityBio (NASDAQ:IBRX) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability and analyst recommendations. Is BBIO or IBRX more profitable? BridgeBio Pharma has a net margin of -329.25% compared to ImmunityBio's net margin of -648.57%. Company Net Margins Return on Equity Return on Assets BridgeBio Pharma-329.25% N/A -85.69% ImmunityBio -648.57%N/A -113.86% Does the media favor BBIO or IBRX? In the previous week, BridgeBio Pharma had 14 more articles in the media than ImmunityBio. MarketBeat recorded 18 mentions for BridgeBio Pharma and 4 mentions for ImmunityBio. ImmunityBio's average media sentiment score of 0.73 beat BridgeBio Pharma's score of 0.72 indicating that ImmunityBio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 10 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ImmunityBio 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings and valuation, BBIO or IBRX? ImmunityBio has lower revenue, but higher earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBridgeBio Pharma$235.81M39.79-$535.76M-$4.09-12.00ImmunityBio$56.60M38.58-$413.56M-$0.48-4.81 Do analysts rate BBIO or IBRX? BridgeBio Pharma currently has a consensus target price of $61.35, suggesting a potential upside of 25.01%. ImmunityBio has a consensus target price of $10.75, suggesting a potential upside of 365.37%. Given ImmunityBio's stronger consensus rating and higher probable upside, analysts plainly believe ImmunityBio is more favorable than BridgeBio Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BridgeBio Pharma 0 Sell rating(s) 0 Hold rating(s) 17 Buy rating(s) 0 Strong Buy rating(s) 3.00ImmunityBio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Which has more risk and volatility, BBIO or IBRX? BridgeBio Pharma has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500. Comparatively, ImmunityBio has a beta of 0.12, suggesting that its share price is 88% less volatile than the S&P 500. Do institutionals & insiders believe in BBIO or IBRX? 99.8% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 8.6% of ImmunityBio shares are held by institutional investors. 18.2% of BridgeBio Pharma shares are held by insiders. Comparatively, 76.8% of ImmunityBio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryBridgeBio Pharma and ImmunityBio tied by winning 8 of the 16 factors compared between the two stocks. Get ImmunityBio News Delivered to You Automatically Sign up to receive the latest news and ratings for IBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IBRX vs. The Competition Export to ExcelMetricImmunityBioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.18B$3.11B$5.75B$9.62BDividend YieldN/A2.23%4.40%4.10%P/E Ratio-4.8121.2831.3026.05Price / Sales38.58345.81432.98193.75Price / CashN/A43.1937.7358.48Price / Book-3.858.129.536.61Net Income-$413.56M-$54.72M$3.26B$265.65M7 Day Performance-9.41%2.62%2.13%2.02%1 Month Performance-22.74%2.68%2.80%-0.31%1 Year Performance-45.65%10.93%30.68%19.06% ImmunityBio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IBRXImmunityBio2.3286 of 5 stars$2.31+3.1%$10.75+365.4%-44.5%$2.18B$56.60M-4.81590BBIOBridgeBio Pharma4.6759 of 5 stars$49.72+1.3%$61.35+23.4%+97.2%$9.46B$221.90M-12.10400Insider TradeVRNAVerona Pharma PLC American Depositary Share2.4034 of 5 stars$105.25+0.1%$109.00+3.6%+290.2%$8.96B$42.28M-106.3130Short Interest ↓ELANElanco Animal Health3.0847 of 5 stars$17.70+1.5%$17.33-2.0%+22.4%$8.80B$4.44B20.599,000Analyst DowngradeBPMCBlueprint Medicines0.4781 of 5 stars$129.46flat$130.00+0.4%N/A$8.36B$562.12M-52.41640ROIVRoivant Sciences3.4303 of 5 stars$11.75+1.5%$16.50+40.5%+2.1%$7.98B$29.05M-16.78860News CoverageInsider TradeGRFSGrifols3.566 of 5 stars$10.59-0.1%$10.30-2.7%+14.8%$7.30B$7.81B9.0723,822Short Interest ↑LEGNLegend Biotech3.7888 of 5 stars$37.16+0.5%$72.38+94.8%-38.0%$6.82B$627.24M-42.172,609RVMDRevolution Medicines4.4078 of 5 stars$35.63+1.0%$68.82+93.1%-14.4%$6.68B$11.58M-7.94250News CoveragePositive NewsAnalyst RevisionRYTMRhythm Pharmaceuticals3.8209 of 5 stars$96.90+0.5%$101.57+4.8%+133.7%$6.43B$156.29M-32.17140News CoveragePositive NewsRNAAvidity Biosciences3.1707 of 5 stars$46.07-0.4%$67.00+45.4%+8.2%$5.95B$10.90M-15.43190Positive NewsInsider TradeOptions Volume Related Companies and Tools Related Companies BBIO Alternatives VRNA Alternatives ELAN Alternatives BPMC Alternatives ROIV Alternatives GRFS Alternatives LEGN Alternatives RVMD Alternatives RYTM Alternatives RNA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IBRX) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunityBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmunityBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access